Development of a novel UHPLC-MS/MS method for quantitative analysis of pirtobrutinib in rat plasma: application to pharmacokinetic study
Abstract Bruton’s tyrosine kinase (BTK) inhibitors play a critical role in the treatment of mantle cell lymphoma (MCL). pirtobrutinib, a new, highly selective, non-covalent BTK inhibitor, was approved by the FDA for the treatment of MCL, chronic lymphocytic leukemia (CLL), and small lymphocytic lymp...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2025-02-01
|
| Serie: | BMC Chemistry |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1186/s13065-025-01424-2 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|